RAC media coverage, page-125

They are not really opposing views, more just views with a lack of understanding about Bisantrene. If you don’t know much about Bisantrene and just think it is another boring chemotherapeutic then you are going to dismiss it. This is a very common response we get from clinicians. It is much easier to tell someone about something completely new than convince them what they think they know is false.

I do find it amusing how they think the problem of the cardiotoxicity of doxorubicin has been “solved”. The current “solution” is to just limit the lifetime dosage to 240mg/m2. Sure this works to prevent damage to the hearts of most patients, but it is at the expense of being able to treat the cancer effectively. Some of the posters seem to have missed that if you used an alternative chemotherapeutic without the cardiotoxicity you could then give far more treatment to the patient.